Debt to Capital Ratio: A measurement of a company's financial leverage, calculated as the company's long-term debt divided by its total capital. Calculated as: Total Long-Term Debt / (Total Long-Term Debt + Shareholders Equity)
Quince Therapeutics, Inc. (QNCX) had Debt to Capital Ratio of 0.59 for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-16.05M |
|
-- |
|
-- |
|
$10.43M |
|
$-10.43M |
|
$-5.55M |
|
$-15.98M |
|
$-15.98M |
|
$-16.05M |
|
$-16.05M |
|
$-16.05M |
|
$-16.05M |
|
$-10.43M |
|
$-10.63M |
|
46.69M |
|
46.69M |
|
$-0.34 |
|
$-0.34 |
|
| Balance Sheet Financials | |
$37.34M |
|
$0.57M |
|
$79.86M |
|
$117.21M |
|
$7.47M |
|
$16.99M |
|
$98.01M |
|
$105.47M |
|
$11.74M |
|
$-55.83M |
|
$11.74M |
|
53.62M |
|
| Cash Flow Statement Financials | |
$-21.02M |
|
$16.94M |
|
$14.50M |
|
$6.21M |
|
$16.83M |
|
$10.61M |
|
$2.66M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.00 |
|
-- |
|
-- |
|
|
Debt to Capital Ratio |
0.59 |
1.45 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-21.29M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-136.75% |
|
28.75% |
|
-13.69% |
|
-55.87% |
|
$0.22 |
|
$-0.46 |
|
$-0.45 |
|